Szynaka Ewa, Petriczko Elżbieta, Grabarek Jerzy, Miklaszewicz Andrzej, Domagala Wenancjusz, Walczak Mieczyslaw
Clinic of Endocrinology, Diabetology, Metabolic Disorders and Cardiology of Developmental Age, Pomeranian Medical University, Poland.
Neuro Endocrinol Lett. 2010;31(4):553-8.
This study aims at assessing how recombinant human growth hormone treatment of children and young people suffering from isolated growth hormone deficiency affects some selected parameters of the immune system: a percentage of lymphocytes, granulocytes, monocytes, concentrations of A, G, and M immunoglobulins, a percentage of T lymphocytes divided into subpopulations CD4 and CD8, a percentage of NK and B lymphocytes, and phagocytic activity of granulocytes and monocytes.
The study comprised 30 children and young people aged 4.2-18 years with isolated growth hormone deficiency both prior to and 6 months after rhGH (recombinant human growth hormone) treatment with a dose of 0.093 IU/kg every 24 hr. The control group comprised 25 healthy children with normal height in the respective age bracket. Labelling was conducted by flow cytometry FACS manufactured by Becton-Dickinson using both labelled antibodies and PHAGOTEST® commercial kit (Orpegen). Concentrations of A, G and M immunoglobulins in blood serum were assessed by means of immunoturbidimetric method using COBAS (manufactured by Roche).
The lowest percentage of active granulocytes in PHAGOTEST® was found in a group examined prior to treatment compared to the control group. The percentage increased after 6 months of rhGH treatment to values comparable with the control group. Although mean concentrations of IgM and IgA after 6 months of treatment with rhGH significantly decreased in comparison with those determined prior to treatment, they still remained within the baseline norm. No significant differences in the phagocytic activity of monocytes, IgG concentration, % of NK lymphocytes, T lymphocytes divided into CD4 and CD8 lymphocytes, B lymphocytes and CD4/CD8 lymphocytic index were found. None of the patients exhibited any clinical symptoms of immune disorders.
rhGH treatment of patients with isolated growth hormone deficiency can have positive influence on the phagocytic activity of scavenger cells, mainly granulocytes, which in children with isolated growth hormone deficiency seems to be lower than in their health peers. Growth hormone treatment of children with isolated growth hormone deficiency does not significantly affect the activity of the immune system expressed by the phagocytic activity of monocytes, the percentage of B, T and NK lymphocytes and IgG concentration in blood serum.
本研究旨在评估重组人生长激素治疗患有单纯性生长激素缺乏症的儿童和青少年对免疫系统某些选定参数的影响：淋巴细胞、粒细胞、单核细胞的百分比，A、G和M免疫球蛋白的浓度，分为CD4和CD8亚群的T淋巴细胞百分比，NK和B淋巴细胞百分比，以及粒细胞和单核细胞的吞噬活性。
本研究包括30名年龄在4.2至18岁之间的患有单纯性生长激素缺乏症的儿童和青少年，在每24小时注射0.093 IU/kg剂量的重组人生长激素（rhGH）治疗前及治疗6个月后。对照组包括25名相应年龄组身高正常的健康儿童。使用Becton-Dickinson生产的流式细胞仪FACS，通过标记抗体和PHAGOTEST®商业试剂盒（Orpegen）进行标记。血清中A、G和M免疫球蛋白的浓度通过使用COBAS（罗氏公司生产）的免疫比浊法进行评估。
与对照组相比，在治疗前检查的组中发现PHAGOTEST®中活性粒细胞的百分比最低。rhGH治疗6个月后，该百分比增加至与对照组相当的值。尽管rhGH治疗6个月后IgM和IgA的平均浓度与治疗前相比显著降低，但仍保持在基线正常范围内。在单核细胞的吞噬活性、IgG浓度、NK淋巴细胞百分比、分为CD4和CD8淋巴细胞的T淋巴细胞、B淋巴细胞和CD4/CD8淋巴细胞指数方面未发现显著差异。没有患者表现出任何免疫紊乱的临床症状。
重组人生长激素治疗单纯性生长激素缺乏症患者可对吞噬细胞（主要是粒细胞）的吞噬活性产生积极影响，在单纯性生长激素缺乏症儿童中，吞噬活性似乎低于健康同龄人。重组人生长激素治疗单纯性生长激素缺乏症儿童对由单核细胞吞噬活性、血清中B、T和NK淋巴细胞百分比以及IgG浓度所表达的免疫系统活性没有显著影响。
